person · Reporting owner

Aurora Daljit Singh

Disclosed activity across 2 companies

Tapewire entity: 20891
SEC CIK: 0001793971

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Neumora Therapeutics, Inc.NMRA · Entity 6115	See Remarks	August 20, 2026	August 21, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Neumora Therapeutics, Inc.

Report date August 20, 2026 · Filed August 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	48,750	Ending reported balance After 2026-08-21 transaction · row 7 4 source rows · reconciled sequence Row 1 · 2026-08-20 · Exercise / conversion · Acquired 67,741 · Balance 116,491 Row 2 · 2026-08-20 · Sale · Disposed 67,741 · Balance 48,750 F1: This transaction was executed in multiple trades at prices ranging from $1.485 to $1.625, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 6 · 2026-08-21 · Exercise / conversion · Acquired 20,553 · Balance 69,303 Row 7 · 2026-08-21 · Sale · Disposed 20,553 · Balance 48,750 F7: This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6379, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Last balance in matching sequence After 2026-08-21 transaction · row 9 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 5 source rows Row 3 · 2026-08-20 · Exercise / conversion · Acquired 21,685 · Balance 21,685 F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Row 4 · 2026-08-20 · Exercise / conversion · Acquired 45,026 · Balance 66,711 F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Row 5 · 2026-08-20 · Sale · Disposed 66,711 · Balance 0 F2: This transaction was executed in multiple trades at prices ranging from $1.48 to $1.6252, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Row 8 · 2026-08-21 · Exercise / conversion · Acquired 21,055 · Balance 21,055 F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Row 9 · 2026-08-21 · Sale · Disposed 21,055 · Balance 0 F8: This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6393, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2034-02-14	Direct	109,527	Reported balance After 2026-08-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-08-20 · Exercise / conversion · Disposed 67,741 · Balance 109,527 F4: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2036-08-20	Direct	200,000	Reported balance After 2026-08-20 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-08-20 · Grant · Acquired 200,000 · Balance 200,000 F6: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2034-02-14	Direct	88,974	Reported balance After 2026-08-21 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-08-21 · Exercise / conversion · Disposed 20,553 · Balance 88,974 F4: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2033-01-19	IndirectSee footnote	0	Reported balance After 2026-08-20 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-08-20 · Exercise / conversion · Disposed 45,026 · Balance 0 F5: The stock option is fully vested and exercisable. F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2031-09-20	IndirectSee footnote	115,853	Reported balance After 2026-08-20 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-08-20 · Exercise / conversion · Disposed 21,685 · Balance 115,853 F5: The stock option is fully vested and exercisable. F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2031-09-20	IndirectSee footnote	94,798	Reported balance After 2026-08-21 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2026-08-21 · Exercise / conversion · Disposed 21,055 · Balance 94,798 F5: The stock option is fully vested and exercisable. F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed in multiple trades at prices ranging from $1.485 to $1.625, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2: This transaction was executed in multiple trades at prices ranging from $1.48 to $1.6252, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.

F4: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

F5: The stock option is fully vested and exercisable.

F6: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

F7: This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6379, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F8: This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6393, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Dermira, Inc.

Report date February 20, 2020 · Filed February 24, 2020

Section 16 reporting ended · disclosed 2020-02-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-02-20 transaction · row 1 1 source row Row 1 · 2020-02-20 · Disposition to issuer · Disposed 30,089 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.36 · Expires 2026-08-07	Direct	Reported balance After 2020-02-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-02-20 · Disposition to issuer · Disposed 67,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.84 · Expires 2027-02-16	Direct	Reported balance After 2020-02-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-02-20 · Disposition to issuer · Disposed 11,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.25 · Expires 2028-02-14	Direct	Reported balance After 2020-02-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-02-20 · Disposition to issuer · Disposed 28,130 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.25 · Expires 2028-02-14	Direct	Reported balance After 2020-02-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-02-20 · Disposition to issuer · Disposed 7,040 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.97 · Expires 2028-02-10	Direct	Reported balance After 2020-02-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-02-20 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.05 · Expires 2029-11-10	Direct	Reported balance After 2020-02-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-02-20 · Disposition to issuer · Disposed 28,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-02-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-02-20 · Disposition to issuer · Disposed 6,250 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-02-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-02-20 · Disposition to issuer · Disposed 574 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-02-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-02-20 · Disposition to issuer · Disposed 2,814 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-02-20 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-02-20 · Disposition to issuer · Disposed 708 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-02-20 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2020-02-20 · Disposition to issuer · Disposed 22,500 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-02-20 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2020-02-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-02-20 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 21, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	21,055	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000385 · form4.xml · derivative · entry 15 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 94,798 Underlying: Common Stock · 21,055 shares Expires 2031-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option is fully vested and exercisable. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 21, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	20,553	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000385 · form4.xml · derivative · entry 14 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,974 Underlying: Common Stock · 20,553 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document
August 21, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	SaleCommon Stock	21,055	$1.60	$33,599.57	Disclosure SEC source: 0001610717-26-000385 · form4.xml · nonDerivative · entry 9 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F8 · price: This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6393, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 21, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	21,055	$0.72	$15,159.60	Disclosure SEC source: 0001610717-26-000385 · form4.xml · nonDerivative · entry 8 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 21,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 21, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	SaleCommon Stock	20,553	$1.59	$32,779.98	Disclosure SEC source: 0001610717-26-000385 · form4.xml · nonDerivative · entry 7 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,750 F7 · price: This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6379, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
August 21, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	20,553	$0.72	$14,798.16	Disclosure SEC source: 0001610717-26-000385 · form4.xml · nonDerivative · entry 6 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 20, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	200,000	$0.00 Strike: $1.52	$0.00	Disclosure SEC source: 0001610717-26-000385 · form4.xml · derivative · entry 13 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2036-08-20 F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document
August 20, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	21,685	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000385 · form4.xml · derivative · entry 12 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 115,853 Underlying: Common Stock · 21,685 shares Expires 2031-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option is fully vested and exercisable. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 20, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	45,026	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000385 · form4.xml · derivative · entry 11 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 45,026 shares Expires 2033-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option is fully vested and exercisable. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 20, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	67,741	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000385 · form4.xml · derivative · entry 10 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,527 Underlying: Common Stock · 67,741 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document
August 20, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	SaleCommon Stock	66,711	$1.51	$101,000.45	Disclosure SEC source: 0001610717-26-000385 · form4.xml · nonDerivative · entry 5 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F2 · price: This transaction was executed in multiple trades at prices ranging from $1.48 to $1.6252, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 20, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	45,026	$0.72	$32,418.72	Disclosure SEC source: 0001610717-26-000385 · form4.xml · nonDerivative · entry 4 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 66,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 20, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	21,685	$0.72	$15,613.20	Disclosure SEC source: 0001610717-26-000385 · form4.xml · nonDerivative · entry 3 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 21,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 20, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	SaleCommon Stock	67,741	$1.51	$102,586.97	Disclosure SEC source: 0001610717-26-000385 · form4.xml · nonDerivative · entry 2 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,750 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.485 to $1.625, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
August 20, 2026 Filed Aug 21, 2026 23:10 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	67,741	$0.72	$48,773.52	Disclosure SEC source: 0001610717-26-000385 · form4.xml · nonDerivative · entry 1 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 19, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	30,918	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000362 · form4.xml · derivative · entry 29 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,026 Underlying: Common Stock · 30,918 shares Expires 2033-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option is fully vested and exercisable. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 19, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	17,732	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000362 · form4.xml · derivative · entry 28 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,268 Underlying: Common Stock · 17,732 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document
August 19, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	13,268	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000362 · form4.xml · derivative · entry 27 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,367 Underlying: Common Stock · 13,268 shares Expires 2033-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document
August 19, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	SaleCommon Stock	30,918	$1.65	$50,887.94	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 18 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F12 · price: This transaction was executed in multiple trades at prices ranging from $1.62 to $1.7006, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 19, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	30,918	$0.72	$22,260.96	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 17 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 30,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 19, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	SaleCommon Stock	31,000	$1.65	$51,029.10	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 16 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,750 F11 · price: This transaction was executed in multiple trades at prices ranging from $1.62 to $1.6995, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
August 19, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	17,732	$0.72	$12,767.04	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 15 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 19, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	13,268	$0.72	$9,552.96	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 14 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 18, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	34,987	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000362 · form4.xml · derivative · entry 26 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 75,944 Underlying: Common Stock · 34,987 shares Expires 2033-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option is fully vested and exercisable. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 18, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	34,162	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000362 · form4.xml · derivative · entry 25 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,635 Underlying: Common Stock · 34,162 shares Expires 2033-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document
August 18, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	SaleCommon Stock	34,987	$1.59	$55,485.88	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 13 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F10 · price: This transaction was executed in multiple trades at prices ranging from $1.48 to $1.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 18, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	34,987	$0.72	$25,190.64	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 12 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 34,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 18, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	SaleCommon Stock	34,162	$1.58	$54,136.52	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 11 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,750 F9 · price: This transaction was executed in multiple trades at prices ranging from $1.49 to $1.645, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
August 18, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	34,162	$0.72	$24,596.64	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 10 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	29,737	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000362 · form4.xml · derivative · entry 24 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 29,737 shares Expires 2033-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option is fully vested and exercisable. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	25,279	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000362 · form4.xml · derivative · entry 23 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 110,931 Underlying: Common Stock · 25,279 shares Expires 2033-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option is fully vested and exercisable. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	1	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000362 · form4.xml · derivative · entry 22 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 999,999 Underlying: Common Stock · 1 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	1,424	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000362 · form4.xml · derivative · entry 21 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,797 Underlying: Common Stock · 1,424 shares Expires 2033-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	15,355	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000362 · form4.xml · derivative · entry 20 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,546 Underlying: Common Stock · 15,355 shares Expires 2033-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionStock Option (Right to Buy) · Derivative	40,890	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0001610717-26-000362 · form4.xml · derivative · entry 19 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,890 shares Expires 2031-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	SaleCommon Stock	55,016	$1.50	$82,782.58	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 9 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F4 · price: This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	29,737	$0.72	$21,410.64	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 8 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 55,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	25,279	$0.72	$18,200.88	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 7 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 25,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	SaleCommon Stock	34,020	$1.49	$50,529.91	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 6 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,750 F2 · price: This transaction was executed in multiple trades at prices ranging from $1.46 to $1.5277, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	SaleCommon Stock	57,670	$1.51	$86,822.19	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 5 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,770 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	1	$0.72	$0.72	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 4 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	1,424	$0.72	$1,025.28	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 3 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	15,355	$0.72	$11,055.60	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 2 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:17 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	Exercise / conversionCommon Stock	40,890	$0.72	$29,440.80	Disclosure SEC source: 0001610717-26-000362 · form4.xml · nonDerivative · entry 1 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 17, 2026 Filed Feb 19, 2026 22:07 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	SaleCommon Stock	6,165	$3.56	$21,916.58	Disclosure SEC source: 0001610717-26-000054 · form4.xml · nonDerivative · entry 1 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,770 F1 · kind: The shares were sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
January 08, 2026 Filed Jan 9, 2026 21:19 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	750,000	$0.00 Strike: $2.33	$0.00	Disclosure SEC source: 0001610717-26-000011 · form4.xml · derivative · entry 1 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2036-01-08 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document
November 11, 2025 Filed Nov 13, 2025 21:39 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	SaleCommon Stock	114,703	$2.68	$307,025.52	Disclosure SEC source: 0001610717-25-000378 · form4.xml · nonDerivative · entry 1 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 22, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $2.65 to $2.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Shares held by Aurora Family Trust. Read SEC document
May 28, 2025 Filed May 30, 2025 22:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	1,000,000	Not disclosed Strike: $0.72	Not disclosed	Disclosure SEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 16 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2035-02-13 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F8 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date Read SEC document
May 28, 2025 Filed May 30, 2025 22:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	195,000	Not disclosed Strike: $0.72	Not disclosed	Disclosure SEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 15 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2034-02-14 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F7 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document
May 28, 2025 Filed May 30, 2025 22:30 UTC	Neumora Therapeutics, Inc. NMRA · Entity 6115	GrantStock Option (Right to Buy) · Derivative	29,737	Not disclosed Strike: $0.72	Not disclosed	Disclosure SEC source: 0000950170-25-079922 · ownership.xml · derivative · entry 14 Aurora Daljit Singh · CIK 0001793971 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 29,737 Underlying: Common Stock · 29,737 shares Expires 2033-06-23 F9 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. F4 · ownership.nature: Shares held by Aurora Family Trust, which members of the Reporting Person's immediate family are the sole beneficiaries. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.